$6.62
-0.33-4.75%
At close: Nov 13, 4:00 PM EST
$6.96
0.345.14%
After Hours: Nov 13, 7:32 AM EST
Kazia Therapeutics Ltd
KZIANASDAQ
Kazia Therapeutics rose 5.8% from $6.26 to $6.62, behind the S&P 500's +12.3%. Its worst day was Jan 2 (−27.4%), and its low came Jan 2 at $5.00.
Nov 14, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kazia Therapeutics shares rose 51.4%, while the S&P 500 rose 0.9%.
+51.4%, the year's best day · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited
+25.6% · S&P 500 +0.1%
Kazia Therapeutics shares fell 20.3%, while the S&P 500 fell 1.1%.
−20.3% · S&P 500 −1.1%
Kazia Therapeutics closed at its lowest level of the year, 20.1% below where the year started.
−27.4%, the year's worst day · S&P 500 +0.2%
EPS of $-0.01 was reported on $60,338.00 revenue.
+2.1% · S&P 500 −0.3%
Kazia Therapeutics shares rose 31.1%, while the S&P 500 rose 0.0%.
+31.1% · S&P 500 0.0%
Kazia Therapeutics closed at its highest level of the year, 170.0% above where the year started.
+15.8% · S&P 500 +0.7%
Where it ended: a close of $6.62 on Nov 13, 2026. Up next: FY 2026 earnings on Nov 27, 2026 (EPS est. $-0.01, revenue est. $60,000.00).
Nothing in the past 12 months.
All KZIA dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KZIA and SPY from Benzinga historical bars. Not investment advice.
